JAY PANDIT Structural Biology

EDUCATION · Ph.D. – Macromolecular Crystallography

EXPERIENCE · BioPharmaWorks - 2018 → present · Pfizer - 1993 - 2018, Structural Biology and Biophysics Group, Lab Head.

EXPERTISE · Protein crystallography, Structure-based drug design, Fragment screening, Target validation. Over 50 patents and scientific publications.

BIO

After 25 years at Pfizer, Jay is now a consultant in the area of structural biology as applied to drug discovery. Jay started the first protein crystallography laboratory at Pfizer in 1993 and spearheaded the growth of the structural biology community at Pfizer since then. He can claim some of the responsibility for the broad and successful adoption of structure-based design principles by the medicinal chemistry community at Pfizer. His lab was responsible for using the full spectrum of structural and biophysical tools to make an impact on therapeutic area decision making in the areas of medicinal chemistry design, target selection and assay development. 

He has worked on successful structure-based design campaigns that have led to clinical candidates in multiple therapeutic areas, covering most major protein families, including kinases, phosphodiesterases, proteases and nuclear hormone receptors. He has led fragment-screening campaigns, using both NMR and x-ray crystallography that have gone from fragment hits to the clinic.

Jay's current research interests are in novel modalities of therapeutic action, such as RNA splicing targets, allosteric inhibitors and targeting sub-cellular localization.